The discussion surrounding Pfizer's stock has been somewhat polarized. Despite a slump in sales due to the COVID pandemic and a decline in its stock price, there are still some investors who firmly believe in the company's long-term prospects. The stock has taken a hit this past year, decreasing about 30% and witnessing a 44% fall in profits. Nonetheless, some estimates show that Pfizer could deliver up to a 30% return with some Wall Street analysts deeming the Pharmacy giant as undervalued and a dividend-yield bargain at its current price.
There are several factors that could fuel a rebound including progress on a once-a-day weight-loss pill and a robust oncology portfolio. However, the company has experienced setbacks too, such as a failure to meet targets with the BioNTech-tied Covid/Flu shot, which has dented investor confidence. Despite these challenges, Pfizer continues to show promise, with some expecting a substantial upside. It has also been attracting attention as it embraces gene therapy and a short seller belief in the stock being one of the best affordable under $40.
However, the question of whether Pfizer could provide millionaire returns seems to be weighing on investors.
Pfizer Stocks News Analytics from Mon, 13 Nov 2023 08:00:00 GMT to Thu, 05 Sep 2024 20:42:15 GMT - Rating 2 - Innovation -7 - Information 7 - Rumor -2
